Utilization of metabonomics to identify serum biomarkers in murine H22 hepatocarcinoma and deduce antitumor mechanism of Rhizoma Paridis saponins

• Published in: Chemico-biological interactions Vol. 256; pp. 55 - 63
• Main Authors: Qiu, Peiyu, Man, Shuli, Yang, He, Fan, Wei, Yu, Peng, Gao, Wenyuan
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier Ireland Ltd 25.08.2016
• Subjects: Animals; Anti-cancer mechanism; Antineoplastic Agents, Phytogenic - chemistry; Antineoplastic Agents, Phytogenic - pharmacology; Antineoplastic Agents, Phytogenic - therapeutic use; Biomarkers, Tumor - blood; Biomarkers, Tumor - metabolism; Drugs, Chinese Herbal - chemistry; Drugs, Chinese Herbal - pharmacology; Drugs, Chinese Herbal - therapeutic use; Female; H22 hepatocarcinoma murine; Liver - drug effects; Liver - metabolism; Liver - pathology; Liver Neoplasms - blood; Liver Neoplasms - drug therapy; Liver Neoplasms - metabolism; Liver Neoplasms - pathology; Magnoliopsida - chemistry; Marker metabolites; Metabolomics - methods; Metabonomics; Mice; Nuclear magnetic resonance; Rhizoma paridis saponins; Rhizome - chemistry; Saponins - chemistry; Saponins - pharmacology; Saponins - therapeutic use; ALP; Ras; Anti-cancer mechanism; PTEN; AUROC; HK2; GLS; p53; LDHA; MCT4; PI3K; RPS; Metabonomics; Myc; RT-PCR; mTOR; Nuclear magnetic resonance; GLUT1; AST; HIF; Rhizoma paridis saponins; ATP5b; PKM; FASN; Marker metabolites; H22 hepatocarcinoma murine; GAPDH
• DOI: 10.1016/j.cbi.2016.06.026
• ISSN: 0009-2797

Murine H22 hepatocarcinoma model is so popular to be used for the preclinical anticancer candidate’s evaluation. However, the metabolic biomarkers of this model were not identified. Meanwhile, Rhizoma Paridis saponins (RPS) as natural products have been found to show strong antitumor activity, while its anti-cancer mechanism is not clear. To search for potential metabolite biomarkers of this model, serum metabonomics approach was applied to detect the variation of metabolite biomarkers and the related metabolism genes and signaling pathway were used to deduce the antitumor mechanisms of RPS. As a result, ten serum metabolites were identified in twenty-four mice including healthy mice, non-treated cancer mice, RPS-treated cancer mice and RPS-treated healthy mice. RPS significantly decreased tumor weight correlates to down-regulating lactate, acetate, N-acetyl amino acid and glutamine signals (p < 0.05), which were marked metabolites screened according to the very important person (VIP), loading plot and receiver operating characteristic curve (ROC) tests. For the analysis of metabolic enzyme related genes, RPS reversed the aerobic glycolysis through activating tumor suppressor p53 and PTEN, and suppressed FASN to inhibit lipogenesis. What’s more, RPS repressed Myc and GLS expression and decreased glutamine level. The regulating PI3K/Akt/mTOR and HIF-1α/Myc/Ras networks also participated in these metabolic changes. Taken together, RPS suppressed ATP product made the tumor growth slow, which indicated a good anti-cancer effect and new angle for understanding the mechanism of RPS. In conclusion, this study demonstrated that the utility of 1H NMR metabolic profiles taken together with tumor weight and viscera index was a promising screening tool for evaluating the antitumor effect of candidates. In addition, RPS was a potent anticancer agent through inhibiting cancer cellular metabolism to suppress proliferation in hepatoma H22 tumor murine, which promoted the application of RPS in the future. [Display omitted] •H22 hepatocarcinoma metabolite biomarkers were identified.•Univariate and multivariate statistical analyses was used in analysis metabolite profiling.•RT-PCR technology was used to evaluate antitumor mechanisms of RPS.•RPS inhibited lipogenesis and glycolysis.•RPS suppressed ATP product supply made the tumor growth slow.